Relay Therapeutics Inc. (RLAY): Price and Financial Metrics

Relay Therapeutics Inc. (RLAY): $7.03

0.10 (-1.40%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add RLAY to Watchlist
Sign Up

RLAY Price/Volume Stats

Current price $7.03 52-week high $18.67
Prev. close $7.13 52-week low $5.95
Day low $6.98 Volume 888,800
Day high $7.18 Avg. volume 1,101,800
50-day MA $8.85 Dividend yield N/A
200-day MA $9.57 Market Cap 922.19M

RLAY Stock Price Chart Interactive Chart >


Relay Therapeutics Inc. (RLAY) Company Bio


Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.


RLAY Latest News Stream


Event/Time News Detail
Loading, please wait...

RLAY Latest Social Stream


Loading social stream, please wait...

View Full RLAY Social Stream

Latest RLAY News From Around the Web

Below are the latest news stories about RELAY THERAPEUTICS INC that investors may wish to consider to help them evaluate RLAY as an investment opportunity.

Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November

The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.

TalkMarkets.com | December 6, 2023

Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 189.21%: Read This Before Placing a Bet

The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to an 189.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 30, 2023

Wall Street Analysts See a 202.33% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?

The consensus price target hints at a 202.3% upside potential for Relay Therapeutics, Inc. (RLAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | November 14, 2023

AI Alert: 3 Healthcare Stocks That Are Investing in Artificial Intelligence

We’re still in the initial stages of a massively disruptive artificial intelligence (AI) boom that's greatly impacting healthcare.

Ian Cooper on InvestorPlace | November 10, 2023

Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at 1:50 p.m. ET. The fireside chat will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webc

Yahoo | November 7, 2023

Read More 'RLAY' Stories Here

RLAY Price Returns

1-mo -13.95%
3-mo -36.09%
6-mo 1.37%
1-year -59.69%
3-year -79.35%
5-year N/A
YTD -36.15%
2023 -26.31%
2022 -51.35%
2021 -26.11%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!